Biotech News

OKYO Pharma Announces Purchase of Shares by Chief Development Officer and Director

OKYO Pharma (OKYO)OKYO PharmaClinical readout

OKYO Pharma Limited (Nasdaq: OKYO ), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced that Gary S. Jacob, PhD, Chief Development Officer and Director of OKYO Pharma has increased his holdings with the purchase of 3,500 of the Company’s ordinary shares on NASDAQ at $1.40 per share, bringing his total holding to 112,420 ordinary shares.

About OKYO Pharma

OKYO Pharma Limited (Nasdaq: OKYO) is a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, with ordinary shares listed for trading on the Nasdaq Capital Market. OKYO plans to initiate a global Phase 3 pivotal clinical trial in the second half of this year, enrolling approximately 111 patients to evaluate a single-dose regimen of urcosimod for the treatment of NCP.

For further information, please visit www.okyopharma.com .

For further inquiries:

OKYO Pharma Ltd Paul Spencer Business Development and Investor Relations +44 (0) 207 495 2379 Email: info@okyopharma.com

Related news

OKYOOKYO Pharma2026-09-09 11:00 EST

OKYO Pharma to Present at Ophthalmology Futures European Forum and iNovation Day at ESCRS 2026

OKYOOKYO Pharma2026-07-20 11:00 EST

OKYO Pharma Announces Filing of Annual Report with Strengthened Cash Position and Accelerated Phase 3 Plans

LCTXLineage Cell Therapeutics2026-11-12 21:03 EST

Lineage Announces Acquisition of NeuroAirmid Therapeutics and Clinical Stage Program for the Treatment of Huntington’s Disease

OCSOculis2026-10-29 09:39 EST

Oculis to Feature Privosegtor’s Neuroprotective Potential and Ongoing PIONEER Program at APOIS Congress and CNS Summit

OCSOculis2026-10-07 06:00 EST

Oculis to Highlight Licaminlimab at Eyecelerator @ AAO 2026 and Partner with Neuro-Ophthalmology Subspecialty Day

PRQRProQR Therapeutics2026-09-09 12:00 EST

ProQR Announces First Participant Dosed in Phase 1 Study of AX-0811 and Virtual Investor and Analyst Educational Event on September 30, 2026

KPRXKiora Pharmaceuticals2026-10-29 11:00 EST

Kiora Pharmaceuticals In-Licenses Late-Stage, Oral Neuroprotective Calpain Inhibitor for Central Retinal Artery Occlusion (CRAO) with Planned Expansion into NAION; Asset Completed Phase 3 Clinical Trial in CRAO in Japan

RHHBYRoche Holdings AG2026-10-21 12:00 EST

Roche presents new pivotal trial data across broad neuroimmunology portfolio at MSToronto2026

OCGNOcugen2026-09-01 11:02 EST

Ocugen Announces First Patient Dosed in Phase 3 Registrational Trial of OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

EYPTEyePoint Pharmaceuticals2026-08-17 11:00 EST

EyePoint Announces Topline Data from LUGANO, the First of Two Pivotal Phase 3 Clinical Trials for DURAVYU™ 2.7mg in Wet AMD

OKYO Pharma

Ocular Pain Drug Developer OKYO Pharma develops therapies for inflammatory and neuropathic eye diseases. Its lead program targets chronic corneal pain, a condition with no specifically approved pharmacologic treatment. Urcosimod Lead Candidate Urcosimod, formerly OK-101, is a lipid-conjugated chemerin peptide agonist of the ChemR23...

Recent company news

Stock data

Close
1.16 USD
Market cap
89.21M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States